Drug intelligence / Profile preview

SV-AI-003

Development stage: Preclinical
Lead developer: SunVax mRNA Therapeutics
Modality: Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intratumoral

Overview

SV-AI-003 is a preclinical-stage in vivo chimeric antigen receptor (CAR) therapy being developed by SunVax mRNA Therapeutics for the treatment of unspecified autoimmune diseases. The therapeutic candidate utilizes SunVax's proprietary Cell Type Specific Delivery (CTSD) lipid nanoparticle (LNP) platform to deliver mRNA encoding a CAR construct directly to specific immune cell populations in vivo. This approach aims to achieve cell-type-specific delivery and in situ engineering of CAR cells, bypassing the need for ex vivo cell manipulation. The specific CAR target has not been publicly disclosed.

Beyond the preview

Go deeper on SV-AI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SV-AI-003.

Explore the full profile